Coronavirus (COVID-19) - Opioid Substitution Treatment (OST) in prisons: process evaluation

Footnotes

1. https://www.gov.scot/publications/coronavirus-covid-19-opiate-substitution-treatment-in-prisons---chief-medical-officer-letter/

2. Available at: https://www.gov.scot/publications/coronavirus-covid-19-clinical-guidance-on-the-use-of-buvidal-in-prisons/

3. Larney, Sarah, et al. "Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study." BMJ open 4.4 (2014). Available at: https://bmjopen.bmj.com/content/bmjopen/4/4/e004666.full.pdf

4. Chapter 2 of this report discusses the scale of OST use in custody in Scotland.

5. Chapter 3 includes data to illustrate the extent of staff resource taken up by the administration of OST.

6. Available at: https://www.nice.org.uk/advice/es19/resources/opioid-dependence-buprenorphine-prolongedrelease-injection-buvidal-pdf-1158123740101

7. Chappuy et al. (2020) "Readiness to try extended-released buprenorphine and related factors of interest: comparison between incarcerated and non-incarcerated subjects with opioid use disorder." Under Review by Harm Reduction Journal. Available at: https://www.researchsquare.com/article/rs-43617/v1 .

8. Sindicich, N., Zador, D., Larney, S., & Dolan, K. (2016). Patient Motivations, Perceptions and Experiences of Opioid Substitution Therapy in Prison. National Drug and Alcohol Research Centre, University of New South Wales. Available at: https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/Technical%20Report%20Number%20332.pdf

9. Available at: http://www.hra-decisiontools.org.uk/ethics/

10. The prescribing data from 19 February 2020 is the latest available. Data is not easily extractable from NHS records.

11. Cornton Vale is a female only prison.

12. The population at HMP Polmont is currently comprised of young people aged 16-21 and adult females.

13. Scottish Government (2020) Scottish prison population: statistics 2019 to 2020: https://www.gov.scot/publications/scottish-prison-population-statistics-2019-20/pages/10/

14. Merrall, E. L., et al. (2010). Meta‐analysis of drug‐related deaths soon after release from prison. Addiction, 105(9), 1545-1554.

15. https://www.scotpho.org.uk/population-groups/prisoners/data/prisoner-health/

16. Sindicich, et al. (2016). Patient Motivations, Perceptions and Experiences of Opioid Substitution Therapy in Prison. National Drug and Alcohol Research Centre, University of New South Wales.

17. Tompkins, et al. (2009). Exploring prison buprenorphine misuse in the United Kingdom: A qualitative study of former prisoners. International Journal of Prisoner Health, 5(2), 71-87.

18. Tompkins, et al. (2009). Exploring prison buprenorphine misuse in the United Kingdom: A qualitative study of former prisoners. International Journal of Prisoner Health, 5(2), 71-87.

19. Middleton et al., (2019) Improved recovery outcomes with injectable prolonged-release buprenorphine in an opioid agonist therapy clinic in Glasgow. Available at: https://www.addiction-ssa.org/wp-content/uploads/2019/11/MiddletonL-Improved-Recovery-Outcomes-With-Injectable-Poster-Oct-19.pdf

20. Condon, L., Gill, H., & Harris, F. (2007). A review of prison health and its implications for primary care nursing in England and Wales: the research evidence. Journal of clinical nursing, 16(7), 1201-1209.